￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

Oncology

Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
New choice for lung cancer: second-generation lung cancer targeted drug aletinib

2025-10-19 11:44:20

Check Details
Data on the efficacy of cabozantinib in patients with RET-rearranged lung cancer

2025-10-19 11:44:20

Check Details
Effects and side effects of erlotinib in the treatment of metastatic lung cancer

2025-10-19 11:44:20

Check Details
Targeted drug alectinib has significant effect in treating non-small cell lung cancer

2025-10-19 11:44:20

Check Details
What are the warnings from the body before lung cancer strikes, and what medicine should be taken

2025-10-19 11:44:20

Check Details
Erlotinib has good efficacy in metastatic non-small cell lung cancer

2025-10-19 11:44:20

Check Details
The second-generation ALK inhibitor, alectinib, is approved by the FDA as a first-line drug for ALK treatment

2025-10-19 11:44:20

Check Details
Has the anti-cancer drug cabozantinib been approved for marketing in China?

2025-10-19 11:44:20

Check Details
Treatment options for patients with metastatic lung cancer-erlotinib

2025-10-19 11:44:20

Check Details
Analysis of the efficacy of erlotinib in the treatment of non-small cell lung cancer

2025-10-19 11:44:20

Check Details
What other drugs can be used for non-small cell lung cancer that have failed two or more chemotherapy regimens?

2025-10-19 11:44:20

Check Details
Erlotinib is a drug for the treatment of locally advanced or metastatic non-small cell lung cancer_ Kanghule

2025-10-19 11:44:20

Check Details
Category
相关知识